The Company’s proprietary technology consists of non-replicating adenovirus and bacterial vectors that can deliver antigens non-invasively (to the nasal passages or to the skin) to elicit a protective immune response. The nasal mucosa and the skin contain cells that participate in the body’s protection mechanism against disease causing pathogens. Vaxin’s technology harnesses this pre-existing feature of our immune system. CLICK FOR MORE INFORMATION

VAXIN & AUBURN UNIVERSITY RECEIVE MILLION DOLLAR GRANT FROM FOUND ANIMALS FOUNDATION TO DEVELOP A VACCINE TO STERILIZE DOGS AND CATS- December 5, 2011
Press Release

VAXIN ANNOUNCES APPOINTMENT OF DR. DAVID DRUTZ CHAIRMAN- October 13, 2011
Press Release

BIRMINGHAM'S VAXIN LANDS $14.7 MILLION FEDERAL GRANT FOR WORK ON ANTHRAX VACCINE - September 25, 2011
Birmingham News

VAXIN AWARDED BARDA CONTRACT VALUED AT UP TO $21.7M TO DEVELOP NEXT GENERATION ANTHRAX VACCINE - September 16, 2011
Press Release

VAXIN ANNOUNCES ANTHRAX VACCINE COLLABORATION AGREEMENT WITH STABILITECH - September 8, 2010
Press Release

HERBERT L. HEYNEKER, PH.D., TO JOIN VAXIN’S BOARD OF DIRECTORS - May 4, 2010
Press Release

VAXIN RECEIVES BIRMINGHAM BUSINESS JOURNAL'S PACESETTER AWARD- April 27, 2010
Press Release

VAXIN CEO CREDITS FLU SCARE FOR ’09 GROWTH - April 22, 2010
Birmingham Business Journal

BIRMINGHAM BIOTECH FIRM VAXIN ADDS HEAVY INDUSTRY HITTERS TO BOARD - February 19, 2010
Birmingham Business Journal

VAXIN ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS- February 19, 2010
Press Release